Trial: 201510167

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Phase

II/III

Principal Investigator

Jacoby, Meagan

Disease Site

Myelodysplastic Syndrome (MDS); Other Hematopoietic

Learn more about this study at: clinicaltrials.gov